General Office of the State Council, Plan for a Pilot Project for the Marketing Authorization Holder System for Pharmaceuticals

国务院办公厅药品上市许可持有人制度试点方案

July 05, 2016 | BY

Susan Mok &clp articles

R&D institutions may apply for MAH qualifications.

Share:

Issued: May 26 2016

Effective: May 26 2016 to November 4 2018

Main contents: A pharmaceutical research and development institution or researcher in a pilot administrative region may, as a pharmaceutical registration applicant (an Applicant), submit a pharmaceutical clinical trial application or pharmaceutical marketing application. If the Applicant secures marketing authorization and a pharmaceutical approval document number, it/he/she may become a marketing authorization holder (an MAH). The legal liability relating to pharmaceutical clinical trials and pharmaceutical production and marketing specified in laws and regulations shall be borne by the Applicant or MAH as appropriate.

An MAH that does not have the appropriate production qualifications must engage a qualified pharmaceutical production enterprise in